Compare MAA & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAA | RLAY |
|---|---|---|
| Founded | 1977 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3B | 1.5B |
| IPO Year | 1994 | 2020 |
| Metric | MAA | RLAY |
|---|---|---|
| Price | $139.20 | $8.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 7 |
| Target Price | ★ $155.25 | $16.00 |
| AVG Volume (30 Days) | 976.9K | ★ 2.2M |
| Earning Date | 02-04-2026 | 11-06-2025 |
| Dividend Yield | ★ 4.40% | N/A |
| EPS Growth | ★ 6.34 | N/A |
| EPS | ★ 4.71 | N/A |
| Revenue | ★ $2,203,402,000.00 | $8,355,000.00 |
| Revenue This Year | $1.82 | $20.47 |
| Revenue Next Year | $2.02 | N/A |
| P/E Ratio | $29.52 | ★ N/A |
| Revenue Growth | ★ 0.92 | N/A |
| 52 Week Low | $125.75 | $1.78 |
| 52 Week High | $173.38 | $9.04 |
| Indicator | MAA | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 65.11 | 57.67 |
| Support Level | $133.10 | $8.13 |
| Resistance Level | $137.61 | $8.76 |
| Average True Range (ATR) | 2.08 | 0.48 |
| MACD | 0.54 | -0.01 |
| Stochastic Oscillator | 97.74 | 54.63 |
Mid-America Apartment Communities Inc or MAA, is a real estate investment trust engaged in the acquisition, operation, and development of multifamily apartment communities located in the southeastern and southwestern United States. The company operates two reportable segments; Same Store includes communities that the Company has owned and have been stabilized for at least a full 12 months as of the first day of the calendar year and Non-Same Store and Other includes recently acquired communities, communities being developed or in lease-up, communities that have been disposed of or identified for disposition, communities that have experienced a casualty loss and stabilized communities that do not meet the requirements to be Same Store communities.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).